Roche Diabetes Care expands exclusive distribution agreement with Senseonics for implantable Eversense CGM system

BASEL, Switzerland -- Roche has expanded its exclusive distribution agreement with Senseonics Holdings, Inc. Under the terms of the agreement, Roche will have exclusive rights to promote, market and sell the implantable Eversense CGM system across Europe, Middle East and Africa, excluding Scandinavia and Israel, while Senseonics will retain responsibility for product development, regulatory approval, quality management, and manufacturing.

The system will be made available to people with diabetes via clinics and medical practices that have been trained on the system. In May of this year, Roche had already signed an exclusive distribution agreement with Senseonics for its three pilot markets Germany, Italy and the Netherlands.

For more information, visit:

Suggested Articles

PCB layout may seem pretty easy, but doing it well takes a different skill set than design

According to a new study by Fact.MR, the MEMS sensor market will grow at a compound annual growth rate of 9% through 2027, reaching $50 billion.

RaayonNova founder and CEO Aleksandr Shtukater is developing advanced contact lens technology that can potentially replace smartphones and tablets.